Center for Genetic Engineering and Biotechnology
 Offices of the CIGB | |
| Research institute overview | |
|---|---|
| Formed | July 1, 1985 |
| Jurisdiction |  Cuba |
| Headquarters | Avenida 31 No. 15802, Havana, Cuba 23°04′26″N 82°27′08″W / 23.0738°N 82.4523°W |
| Website | www |
The Center for Genetic Engineering and Biotechnology (Spanish: Centro de Ingeniería Genética y Biotecnología, CIGB) is a research institute in Havana, Cuba. It is responsible for creating the Abdala vaccine.[1][2][3]
The Centre developed the COVID-19 vaccine Mambisa which is in the final stages of clinical trials.[4]
See also
References
- ^ "Cuba's COVID vaccine rivals BioNTech-Pfizer, Moderna". DW.COM. 2021-06-27. Retrieved 2021-06-28.
- ^ "ABDALA Clinical Study - Phase III". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Archived from the original on 2021-03-20. Retrieved March 22, 2021.
- ^ "ABDALA Clinical Study". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Archived from the original on 2021-01-22. Retrieved March 22, 2021.
- ^ Sánchez, Liz Conde (7 April 2022). "How is Mambisa progressing on the road to authorization as an anti-COVID-19 vaccine?". en.granma.cu. Retrieved 6 May 2022.
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 | This Cuba-related article is a stub. You can help Wikipedia by expanding it. |